Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

57 Vicioso MA, Garaud JJ, Reglier-Poupet
H, Lebeaut A, Gougerot-Pocidalo
MA, Chollet-Martin S. Moderate
inhibitory effect of interleukin-10 on
human neutrophil and monocyte chemotaxis
in vitro. Eur Cytokine Netw
1998; 9: 247±53.
58 Del Prete G, De Carli M, Almerigogna
F, Giudizi MG, Biagiotti R,
Romagnani S. Human IL-10 is produced
by both type 1 helper (T h1) and
type 2 helper (Th2) T cell clones and inhibits
their antigen-specific proliferation
and cytokine production. J Immunol
1993; 150: 353±60.
59 Groux H, Bigler M, de Vries JE, Roncarolo
MG. Interleukin-10 induces a
long-term antigen-specific anergic state
in human CD4 + T cells. J Exp Med
1996; 184: 19±29.
60 Asadullah K, Sterry W, Stephanek K,
et al. IL-10 is a key cytokine in psoriasis.
Proof of principle by IL-10 therapy: a new
therapeutic approach. J Clin Invest 1998;
101: 783±94.
61 Joss A, Akdis M, Faith A, Blaser K,
Akdis CA. IL-10 directly acts on T cells
by specifically altering the CD28 co-stimulation
pathway. Eur J Immunol 2000;
30: 1683±90.
62 Groux H, O'Garra A, Bigler M, et al.
A CD4 + T-cell subset inhibits antigenspecific
T-cell responses and prevents
colitis. Nature 1997; 389: 737±42.
63 Zeller JC, Panoskaltsis-Mortari A,
Murphy WJ, Ruscetti FW, Narula S,
Roncarolo MG, Blazar BR. Induction
of CD4 + T cell alloantigen-specific hyporesponsiveness
by IL-10 and TGF-b.
J Immunol 1999; 163: 3684±91.
64 Levings MK, Sangregorio R, Galbiati
F, Squadrone S, de Waal Malefyt
R, Roncarolo MG. IFN-a and IL-
10 induce the differentiation of human
type 1 Tregulatory cells. J Immunol
2001; 166: 5530±9.
65 Levings MK, Sangregorio R, Roncarolo
MG. Human CD25(+)CD4(+) T
regulatory cells suppress naive and
memory T cell proliferation and can be
expanded in vitro without loss of function.
J Exp Med 2001; 193: 1295±302.
66 Jonuleit H, Schmitt E, Schuler G,
Knop J, Enk AH. Induction of interleu-
References
kin 10-producing, nonproliferating
CD4(+) T cells with regulatory properties
by repetitive stimulation with allogeneic
immature human dendritic
cells. J Exp Med 2000; 192: 1213±22.
67 Groux H, Bigler M, de Vries JE, Roncarolo
MG. Inhibitory and stimulatory
effects of IL-10 on human CD8 + T cells.
J Immunol 1998; 160: 3188±93.
68 Santin AD, Hermonat PL, Ravaggi
A, et al. Interleukin-10 increases T h1 cytokine
production and cytotoxic potential
in human papillomavirus-specific
CD8(+) cytotoxic T lymphocytes. J Virol
2000; 74: 4729±37.
69 Cai G, Kastelein RA, Hunter CA. IL-
10 enhances NK cell proliferation, cytotoxicity
and production of IFN-g when
combined with IL-18. Eur J Immunol
1999; 29: 2658±65.
70 Levy Y, Brouet JC. Interleukin-10 prevents
spontaneous death of germinal
center B cells by induction of the bcl-2
protein. J Clin Invest 1994; 93: 424±8.
71 Rousset F, Peyrol S, Garcia E, et al.
Long-term cultured CD40-activated B
lymphocytes differentiate into plasma
cells in response to IL-10 but not IL-4.
Int Immunol 1995; 7: 1243±53.
72 Jeannin P, Lecoanet S, Delneste Y,
Gauchat JF, Bonnefoy JY. IgE versus
IgG4 production can be differentially
regulated by IL-10. J Immunol 1998;
160: 3555±61.
73 Defrance T,Vanbervliet B, Briere F,
Durand I, Rousset F, Banchereau J.
Interleukin 10 and transforming
growth factor b cooperate to induce
anti-CD40-activated naive human B
cells to secrete immunoglobulin A.
J Exp Med 1992; 175: 671±82.
74 Cassatella MA, Meda L, Bonora S,
Ceska M, Constantin G. Interleukin
10 (IL-10) inhibits the release of proinflammatory
cytokines from human
polymorphonuclear leukocytes. Evidence
for an autocrine role of tumor necrosis
factor and IL-1 b in mediating
the production of IL-8 triggered by lipopolysaccharide.
J Exp Med 1993; 178:
2207±11.
75 Kasama T, Strieter RM, Lukacs NW,
Burdick MD, Kunkel SL. Regulation
of neutrophil-derived chemokine ex-
171